2200 PENNSYLVANIA AVE NW, WASHINGTON, DC
Shareholder Meeting Results - Election of Directors and Auditor Ratification
Reports First Quarter 2026 Financial Results
Annual Report to Security Holders
Appoints Dr. Charles Duncan to its Board of Directors
Executive Departure - Timothy Williams Resigns as SVP, General Counsel
FDA Approves Vanda's BYSANTI for Bipolar I and Schizophrenia
Changes in Board, Management or Compensation
Financial Results, Press Release
Q1
FY 2024
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Amended Registration of Securities
Registration of Securities
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Correspondence
Submission Upload
Confidential Treatment Order